Sign in
Taking people in South KoreaNo phase

Tests whether opening blocked heart arteries helps weak hearts

Compares artery-opening procedures with medicine alone in adults with weakened hearts from blocked arteries.

Key facts

Who runs it
Samsung Medical Center
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Revascularization Versus Medical Treatment in Patients With Ischemic Left Ventricular Dysfunction
Status
Recruiting
People taking part
900 people, planned
Started
16 Jun 2023
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Percutaneous coronary intervention
Record updated
14 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure and a weak heart pump caused by narrowed heart arteries. It compares opening the arteries (PCI) with medicines alone.

Age
At least 19 years old.
Sex
All sexes can join.
Disease stage
Stage C heart failure with left ventricular ejection fraction below 40%. Coronary artery narrowing of more than 50% with proven reduced blood flow to the heart muscle. The narrowing can be treated with PCI.
Biomarker or test result
Reduced blood flow to the heart muscle shown by invasive physiologic assessment during a heart artery test.

Main reasons for not taking part

  • Heart attack within 4 weeks before randomization
  • Heart muscle that is no longer alive on a viability test
  • Needing a left ventricular assist device or a heart transplant now
  • Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
  • Pregnancy or breast feeding

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Subject must be at least 19 years of age
  • Patients with stage C heart failure and left ventricular ejection fraction<40%
  • Patients with significant coronary artery stenosis (diameter stenosis>50% with proven inducible myocardial ischemia by invasive physiologic assessment)
  • Coronary artery disease is amenable for percutaneous coronary intervention (PCI)
  • Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive approach and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure

Who cannot take part

  • Myocardial infarction by universal definition within 4 weeks of randomization
  • Non-viable myocardium in myocardial viability test (cardiac magnetic resonance, dobutamine-stress echocardiography, delayed single-photon emission computerized tomography, or aneurysmal change in echocardiography)
  • Patients who need left ventricular assisted device (LVAD) or heart transplantation at the time of randomization
  • Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
  • Non-cardiac co-morbid conditions are present with life expectancy <2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • Target lesions not amenable for PCI by operators' decision
  • Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
  • Pregnancy or breast feeding
  • Unwillingness or inability to comply with the procedures described in this protocol

Where in South Korea

  • Samsune Medical CenterSeoul, South KoreaContact: Young Bin Song, MD, PhDTaking people

About the trial

What the trial wants to find out

Randomized trial to compare clinical outcomes between revascularization versus medical treatment alone in patients with ischemic cardiomyopathy and left ventricular dysfunction.

The 2 groups in the trial

  • Guideline-directed medical treatment groupNo study treatment, for comparison

    In the GDMT group, medical treatment for patients with left ventricular dysfunction will be performed under current ACC/AHA/SCAI or ESC/EACTS guidelines for heart failure.

  • Revascularization groupTreatment being tested

    In the revascularization group, patients will undergo percutaneous coronary intervention (PCI) using standard techniques under current ACC/AHA/SCAI or ESC/EACTS guidelines. In the revascularization group, the procedure must be within 2 weeks of randomization. Revascularization criteria is presented as below. Revascularization indication 1. Diameter stenosis \>90% by visual assessment 2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89) 3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory. * Left main artery * Proximal to mid left anterior descending artery * Proximal left circumflex artery in left dominant coronary arterial system * Proximal to distal right coronary artery in right dominant coronary arterial system

    Treatment: Percutaneous coronary intervention

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Controlled Trial of Revascularization Versus Medical Treatment on Clinical Outcomes in Patients With Reduced Left Ventricular Function
Plain-language title
Tests whether opening blocked heart arteries helps weak heartsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 March 2025